Alam et al. reported that there was a widespread inactivation mutation of histone methyltransferase KMT2D in lung cancer, leading to impaired function of super enhancers and downregulation of PER2 (an inhibitor of glycolysis protein) expression, which promotes the glycolysis process in lung cancer cells and achieves the effect of promoting tumor growth [84]. This evidence concerns the gene PRDM9 and lung cancer.